^
Association details:
| Biomarker: | GNRH1 expression |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Zoptrex (zoptarelin doxorubicin) (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
Published date:
01/14/2020
Excerpt:
Expression and cellular distribution of the full length LHRH receptor type I in OCM3 cells was demonstrated by RT-PCR and by immunocytochemistry….In order to investigate whether AEZS-108 inhibits cell proliferation and its extent, OCM3 cells were treated either with 5 µM AEZS-108 or equal amount of doxorubicin. MTS assay was performed after 24 and 48 hours of treatment. AEZS-108 and doxorubicin have been shown to reduce cell proliferation by 36.3% (p < 0.001) and 62.9% (p < 0.001) respectively after 24 hours, and by 84.7% (p < 0.001) and 89.7% (p < 0.001) respectively after 48 hours...
Secondary therapy:
doxorubicin hydrochloride
DOI:
https://doi.org/10.18632/oncotarget.27431
